Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Nov-21 9:02 AM View:  | Dable Habib J CEO and President Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 98,450 | -- | -- | (100%) 98.45K to 0 | |
| 22-Nov-21 9:10 AM View: | Hite Christopher Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 930 | -- | -- | (100%) 0.93K to 0 | |
| 22-Nov-21 9:12 AM View: | Zakrzewski Joseph S Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 34,499 | -- | -- | (100%) 34.5K to 0 | |
| 22-Nov-21 9:05 AM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 23,423 | -- | -- | (100%) 23.42K to 0 | |
| 22-Nov-21 9:03 AM View: | McLaughlin Kevin F SVP, CFO and Treasurer | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 10,681 | -- | -- | (100%) 10.68K to 0 | |
| 22-Nov-21 9:11 AM View: | Malik Kemal Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 1,622 | -- | -- | (100%) 1.62K to 0 | |
| 22-Nov-21 9:08 AM View: | Kearney Terrence C Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 6,749 | -- | -- | (100%) 6.75K to 0 | |
| 22-Nov-21 9:09 AM View: | Smith Karen L. Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 1,622 | -- | -- | (100%) 1.62K to 0 | |
| 22-Nov-21 9:06 AM View: | Nader Francois Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 6,749 | -- | -- | (100%) 6.75K to 0 | |
| 22-Nov-21 9:04 AM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 18,509 | -- | -- | (100%) 18.51K to 0 | |
| 22-Nov-21 9:08 AM View: | McCourt Thomas A Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 6,044 | -- | -- | (100%) 6.04K to 0 | |
| 22-Nov-21 9:04 AM View: | Backstrom Jay T. EVP, Research and Development | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 21,233 | -- | -- | (100%) 21.23K to 0 | |
| 22-Nov-21 9:07 AM View: | Hamill Laura Director | Acceleron Pharma Inc (XLRN) | 19-Nov-21 | Disposition (change in control) | 474 | -- | -- | (100%) 0.47K to 0 | |
| 12-Nov-21 4:15 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 09-Nov-21 | Option Exercise | 4,500 | $29.37 | $132,165.00 | 24% 18.92K to 23.42K | |
| 27-Sep-21 7:21 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 27-Sep-21 | Market Option Sale (Planned) | 5,000 | $175.00 | $875,000.00 | (21%) 23.51K to 18.51K | (3%) |
| 27-Sep-21 7:21 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 27-Sep-21 | Option Exercise | 5,000 | $40.61 | $203,050.00 | 27% 18.51K to 23.51K | |
| 24-Sep-21 10:00 PM View: | McLaughlin Kevin F SVP, CFO and Treasurer | Acceleron Pharma Inc (XLRN) | 24-Sep-21 | Market Option Sale (Planned) | 5,370 | $160.38 | $861,241.00 | (33%) 16.05K to 10.68K | (12%) |
| 24-Sep-21 10:00 PM View: | McLaughlin Kevin F SVP, CFO and Treasurer | Acceleron Pharma Inc (XLRN) | 24-Sep-21 | Option Exercise | 5,370 | $40.64 | $218,251.00 | 50% 10.68K to 16.05K | |
| 24-Sep-21 10:00 PM View: | McLaughlin Kevin F SVP, CFO and Treasurer | Acceleron Pharma Inc (XLRN) | 23-Sep-21 | Option Exercise | 19,630 | $39.67 | $778,624.00 | 184% 10.68K to 30.31K | |
| 24-Sep-21 10:00 PM View: | McLaughlin Kevin F SVP, CFO and Treasurer | Acceleron Pharma Inc (XLRN) | 23-Sep-21 | Market Option Sale (Planned) | 19,630 | $160.31 | $3,146,890.00 | (65%) 30.31K to 10.68K | (12%) |
| 22-Sep-21 10:00 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 21-Sep-21 | Market Option Sale (Planned) | 6,650 | $150.05 | $997,832.00 | (26%) 25.57K to 18.92K | (20%) |
| 22-Sep-21 10:00 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 21-Sep-21 | Option Exercise | 5,000 | $40.61 | $203,050.00 | 27% 18.51K to 23.51K | |
| 22-Sep-21 10:00 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 21-Sep-21 | Option Exercise | 6,650 | $32.58 | $216,624.00 | 35% 18.92K to 25.57K | |
| 22-Sep-21 10:00 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 21-Sep-21 | Market Option Sale (Planned) | 5,000 | $150.03 | $750,150.00 | (21%) 23.51K to 18.51K | (20%) |
| 09-Sep-21 5:07 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 09-Sep-21 | Market Sale (Planned) | 1,407 | $130.00 | $182,910.00 | (7%) 20.33K to 18.92K | (38%) |
| 09-Sep-21 5:07 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 08-Sep-21 | Market Sale (Planned) | 6 | $130.00 | $780.00 | (< 1%) 20.34K to 20.33K | (38%) |
| 09-Sep-21 5:07 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 07-Sep-21 | Payment of Exercise | 587 | $129.36 | $75,934.30 | (3%) 20.92K to 20.34K | (39%) |
| 02-Jul-21 9:15 PM View: | Dable Habib J CEO and President Director | Acceleron Pharma Inc (XLRN) | 02-Jul-21 | Option Exercise | 42,186 | $35.04 | $1,478,200.00 | 43% 98.45K to 140.64K | |
| 02-Jul-21 9:15 PM View: | Dable Habib J CEO and President Director | Acceleron Pharma Inc (XLRN) | 02-Jul-21 | Market Option Sale (Planned) | 42,186 | $126.97 | $5,356,350.00 | (30%) 140.64K to 98.45K | (42%) |
| 02-Jul-21 9:15 PM View: | Dable Habib J CEO and President Director | Acceleron Pharma Inc (XLRN) | 01-Jul-21 | Option Exercise | 57,814 | $35.04 | $2,025,800.00 | 59% 98.45K to 156.26K | |
| 02-Jul-21 9:15 PM View: | Dable Habib J CEO and President Director | Acceleron Pharma Inc (XLRN) | 01-Jul-21 | Market Option Sale (Planned) | 57,814 | $126.73 | $7,326,590.00 | (37%) 156.26K to 98.45K | (42%) |
| 08-Jun-21 6:53 PM View: | Veness Adam M SVP, General Counsel and Sec. | Acceleron Pharma Inc (XLRN) | 07-Jun-21 | Payment of Exercise | 108 | $126.69 | $13,682.50 | (< 1%) 21.03K to 20.92K | (42%) |
| 21-Apr-21 4:46 PM View: | McCourt Thomas A Director | Acceleron Pharma Inc (XLRN) | 19-Apr-21 | Market Option Sale (Planned) | 7,500 | $119.26 | $894,425.00 | (55%) 13.54K to 6.04K | (51%) |
| 21-Apr-21 4:46 PM View: | McCourt Thomas A Director | Acceleron Pharma Inc (XLRN) | 19-Apr-21 | Option Exercise | 7,500 | $40.61 | $304,575.00 | 124% 6.04K to 13.54K | |
| 05-Apr-21 8:17 PM View: | Smith Karen L. Director | Acceleron Pharma Inc (XLRN) | 05-Apr-21 | Option Exercise | 8,925 | $40.72 | $363,404.00 | 196% 4.56K to 13.49K | |
| 05-Apr-21 8:17 PM View: | Smith Karen L. Director | Acceleron Pharma Inc (XLRN) | 05-Apr-21 | Market Sale (Planned) | 2,939 | $140.18 | $412,004.00 | (64%) 4.56K to 1.62K | (28%) |
| 05-Apr-21 8:27 PM View: | Zakrzewski Joseph S Director | Acceleron Pharma Inc (XLRN) | 05-Apr-21 | Option Exercise | 10,000 | $24.11 | $241,100.00 | 29% 34.5K to 44.5K | |
| 05-Apr-21 8:17 PM View: | Smith Karen L. Director | Acceleron Pharma Inc (XLRN) | 05-Apr-21 | Market Option Sale (Planned) | 8,925 | $140.18 | $1,251,150.00 | (66%) 13.49K to 4.56K | (28%) |
| 05-Apr-21 8:27 PM View: | Zakrzewski Joseph S Director | Acceleron Pharma Inc (XLRN) | 05-Apr-21 | Market Option Sale (Planned) | 10,000 | $140.73 | $1,407,340.00 | (22%) 44.5K to 34.5K | (28%) |
| 02-Apr-21 6:08 PM View: | Zakrzewski Joseph S Director | Acceleron Pharma Inc (XLRN) | 01-Apr-21 | Option Exercise | 10,000 | $24.11 | $241,100.00 | 29% 34.5K to 44.5K | |
| 02-Apr-21 6:00 PM View: | Smith Karen L. Director | Acceleron Pharma Inc (XLRN) | 01-Apr-21 | Market Option Sale (Planned) | 8,925 | $136.47 | $1,218,000.00 | (66%) 13.49K to 4.56K | (32%) |
| 02-Apr-21 6:08 PM View: | Zakrzewski Joseph S Director | Acceleron Pharma Inc (XLRN) | 01-Apr-21 | Market Option Sale (Planned) | 10,000 | $134.64 | $1,346,380.00 | (22%) 44.5K to 34.5K | (33%) |
| 02-Apr-21 6:00 PM View: | Smith Karen L. Director | Acceleron Pharma Inc (XLRN) | 01-Apr-21 | Option Exercise | 8,925 | $40.72 | $363,404.00 | 196% 4.56K to 13.49K | |
| 04-Mar-21 5:17 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 02-Mar-21 | Market Option Sale (Planned) | 5,000 | $136.01 | $680,059.00 | (20%) 24.4K to 19.4K | (32%) |
| 04-Mar-21 5:17 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 02-Mar-21 | Option Exercise | 5,000 | $40.61 | $203,050.00 | 26% 19.4K to 24.4K | |
| 08-Jun-21 6:48 PM View: | Kango Sujay EVP, Chief Commercial Officer | Acceleron Pharma Inc (XLRN) | 12-Feb-21 | Payment of Exercise | 887 | $130.87 | $116,082.00 | (5%) 19.4K to 18.51K | (37%) |
| 02-Feb-21 6:49 PM View: | McCourt Thomas A Director | Acceleron Pharma Inc (XLRN) | 29-Jan-21 | Grant | 1,622 | -- | -- | 37% 4.42K to 6.04K | |
| 02-Feb-21 7:15 PM View: | Backstrom Jay T. EVP, Research and Development | Acceleron Pharma Inc (XLRN) | 29-Jan-21 | Grant | 5,409 | -- | -- | 35% 15.37K to 20.78K | |
| 02-Feb-21 7:46 PM View: | McLaughlin Kevin F SVP, CFO and Treasurer | Acceleron Pharma Inc (XLRN) | 29-Jan-21 | Grant | 4,868 | -- | -- | 84% 5.81K to 10.68K | |
| 02-Feb-21 6:46 PM View: | Malik Kemal Director | Acceleron Pharma Inc (XLRN) | 29-Jan-21 | Grant | 1,622 | -- | -- | 100% 0 to 1.62K |
